Group items tagged

The global anti-obesity Drugs Market is segmented in by product:-Peripherally acting anti-obesity agents, centrally acting anti-obesity drugs; by mode of action:-Fat Absorption Inhibition, Food Intake Suppression:- Noradrenergic Drugs, Serotoninergic Drugs, Adrenergic Drug, Others; Increase Thermogenesis; Segmentation by Type:- Prescription Drugs, Over the Counter Drugs; Segmentation by Distribution Channel:- Hospital Pharmacy, Retail Pharmacy and by regions. Anti-Obesity Drugs Market is anticipated to mask a significant CAGR during the forecast period i.e. 2015-2021. Anti-obesity drugs are pharmacological agents that are used to lose cholesterol and reduce the body weight. These drugs generally show their action by altering the fundamental functioning of the normal body by utilization of calories or by altering the appetite. The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese

The Department of Health (DoH) is inviting the public to share their views on a new Regional Obesity Management Service and a new Obesity Strategic Framework. A public consultation has been launched on the Healthy Futures strategic framework, which aims to prevent the harm caused by obesity, and improve diets and levels of physical activity of people. The Department is also seeking views on its plans to introduce a new service that would focus on the introduction of specialist support, weight loss medication, and bariatric surgery to help people living with obesity. Northern Ireland is seeing an increase in obesity rates, with the latest Health Survey NI data showing that 65 per cent of adults and 26 per cent of children in the country are either obese or overweight.

A roundtable organised by National Pharmacists Association (NPA) discussed how an enhanced role of community pharmacies could help people with obesity. Seven action points were recommended by the delegates at the virtual event which took place on March 31, in collaboration with Novo Nordisk. It was chaired by Professor Maggie Rae, president of the Faculty of Public Health and featured representatives from the Royal Pharmaceutical Society, Royal Society for Public Health, Patients Association, UK Health Security Agency, Diabetes UK and NHS England. The roundtable also heard testimony from a parent of a young adult living with obesity and a presentation of the personal experience of someone living with the condition by Sarah Le Brocq, director of campaign group, All About Obesity.

Obesity is defined by body mass index more than 30. Body mass index is derived from your weight and height. Obesity is now rising across many countries in the world including India. It is said to have reached an epidemic proportion in our country with 5 % of the population being morbidly obese.

Obesity is defined by body mass index more than 30. Body mass index is derived from your weight and height. Obesity is now rising across many countries in the world including India. It is said to have reached an epidemic proportion in our country with 5 % of the population being morbidly obese.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

Obesity rates have increased alarmingly in the last 10 years. It has become a rising epidemic in the world. It's not a cosmetic issue, anymore. Statistics suggest that the obesity rates have been increased alarmingly by more than 60% in the last 10 years. The condition has worsened so much that it has become a rising epidemic in the United States as well. So, it can't be considered a cosmetic issue, anymore. It is the second-leading cause of death across […]

Germany's Boehringer Ingelheim said on Thursday (Aug 17) it would conduct three late-stage studies for its obesity drug candidate after it showed up to 19 per cent weight loss after 46 weeks in a mid-stage trial. The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will evaluate the drug's safety and efficacy, Boehringer said, and added that it would provide further details on the studies before initiation. Boehringer and Zealand are among global drugmakers racing to grab a share of the potential $100 billion market for obesity treatments within a decade. Survodutide works by mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), which suppresses appetite, as well as imitating another gut hormone called glucagon that helps break down fat.

Amgen's experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday (December 3). The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

Being overweight can increase your chances of having bad cholesterol in your blood. Due to high cholesterol, a person can suffer from heart related diseases. According to doctor's research, a 10-pound increase in body weight produces 10 milligrams of cholesterol in the body. Consuming unhealthy and calorie-rich foods also leads to obesity in individuals. Junk foods, such as burgers, fries, and pizza, are high in calories, which ultimately lead to this disorder. Research results show that low-liquid fructose can significantly affect glucose metabolism and lead to metabolic syndrome and fatty liver syndrome. Metabolic syndrome also includes type 2 diabetes, high blood pressure, and heart disease. One of the main reasons people develop this disorder is lack of physical activity. Most people have jobs that involve little or no physical activity for most of the day. As a result, such individuals do not use their calories and these excess calories lead to obesity. The best way to treat this disorder is to use Phentermine 37.5mg Obesity Pills Online.

More pharmacies should do NHS Health Checks to improve access, a new study that focuses on ways to improve the lives of people living with obesity, recommends. The report, Levelling Up Obesity Care, by pharma giant Novo Nordisk follows a series of roundtables with patient advocates, healthcare professionals and academics to generate understanding on the future of obesity care in England. Amongst its recommendations, the report says that 'to widen access and alleviate pressure on GP services, consideration should be given to expanding NHS Health Checks in community pharmacy'. NHS Health Checks include a measurement of Body Mass Index (BMI). Those most likely to benefit from a Health Check include people who live in more deprived areas, and are more likely to be living with obesity, says the report.

We know obesity can affect you mentally, physically, and you want your charm and confidence back. Get the Best Obesity Treatment in Delhi with Dr Hemi

The Disease They Call FAT is best solutions and treatment for Obesity in New York and surrounding the area. This film introduces us to a disease hiding in plain sight, and makes a compelling case that it is time to end the suffering.

Dr. Suyog Dandekar, driving force behind western Maharashtra's premier ayurvedic health destination- Prakruti health resort, explains ayurvedic tips on Obesity and Spondylosis. Also know the panchakarma treatment for obesity and spondylosis.

Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through registered healthcare professionals. Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK. The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage. "We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access to and continuity of treatment for people living with obesity."

Being overweight can increase your chances of having bad cholesterol in your blood. Due to high cholesterol, a person may suffer from heart related diseases. According to doctor's research, a 10-pound increase in body weight produces 10 milligrams of cholesterol in the body. The body naturally needs cholesterol, and the liver makes the waxy substance to build the body's cells. Cholesterol is very useful for the body to produce vitamin D, which is essential for a healthy immune system. Fat creates triglycerides, which build up in our liver, creating too many triglycerides, which lead to the possibility of high cholesterol. If there is too much LDL (low-density lipoprotein) in the blood, which accumulates fat, this waxy substance can clog your arteries, leading to a heart attack or stroke. Research results show that low-liquid fructose can significantly affect glucose metabolism and lead to metabolic syndrome and fatty liver syndrome. Metabolic syndrome also includes type 2 diabetes, high blood pressure, and heart disease. The best treatment for reducing obesity is to use OTC obesity medications, such as Phentermine 37.5-mg, which you can easily buy from Pharma Health online.

Erectile dysfunction is a very common form of medical condition that occurs in males over time. Usually, this problem is found in people who take too much medication, and ED is probably a side effect of any one of them. However, in seventy-five percent of males, the cause of erectile dysfunction is unknown, and finding the accurate reason for it is very complex. It can be a result of any neural complications, diabetes, or any surgeries that include the prostate of our body. ED can also be treated by using a vacuum device and surgeries on the private parts. However, it can be eradicated completely without any surgeries, and here are some tips that will help you in overcoming erectile dysfunction without surgery and lead a happy life. DO EXERCISE Exercise is a great way to overcome any health issues, and also to safeguard yourself from health issues in the future. Physical activity also helps you in controlling obesity, which is one of the reasons behind ED. By not doing regular exercises, you expose yourself to various cardiovascular problems, which contribute to ED. Studies show that light aerobic exercise for 30-40 minutes a day for at least four times a week for at least 6 months has considerably reduced ED in people. STAY SLIM Studies have shown that a person who has a waist near 42 inches is more likely to suffer from ED than a person with a waistline of 32 inches. Therefore, if you are obese it's time that you lose some weight. Excessive fat in the body is the birthplace of various diseases. Obesity is also responsible for vascular problems and diabetes which are two primary causes of ED.

A new research has suggested that meat contributes to the growing global obesity prevalence as much as sugar and moreover it is protein, not the fat present in meat which is a major obesity contributor. Proteins digest slow as compared to fats Carbohydrates and fats not only provide us with enough energy, the body demands, they are also digested faster than protein.